RFK Jr. peptide policy could boost Hims & Hers as its GLP-1 business changes

Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.

Published: April 16, 2026 5:44 pm

Source: CNBC — Read original